The "Victory" Reaction: A Three Component Synthesis of Pyrido[2,3-d]pyrimidines
Poster Jun 27, 2006
Núria Mont, Jordi Teixidó, José I. Borrell, and C. Oliver Kappe
Pedro Victory (1928-1994) spent most of his scientific career studying the synthetic applications of 2-methoxy-6-oxo-1,4,5,6-tetrahydropyridin-3-carbonitriles 3.1 The presence of a methoxy group in pyridones 3 in the ß- position of an a,ß-unsaturated cyano group, which is also conjugated with the lactam NH, render such compoundexcellent substrates for the ethylenic nucleophilic substitution.
This approach allowed us to describe genera lprocedures for the synthesis of pyrazolo[3,4-b]pyridines, 1,6-naphthyridines and 4-aminopyrido[2,3-d]pyrimidinesby treatment of 3 with amidine systems 5. More recently, we described an acyclic strategy for the synthesis of compounds 6 based on the isolation of the corresponding Michael adduct 4 that allowed us to obtain 4-oxopyrido[2,3-d]pyrimidines 6 (R3 = OH).2
Here, we report our preliminary results that pyridopyrimidines 6 can be obtained in a single step as a result of a one-pot three component reaction using controlled microwave-assisted synthesis (Emrys Synthesizer).
Bioluminescent Kinase Profiling Systems For Characterizing Small Molecule Kinase InhibitorsPoster
In order to profile compounds against a broad panel of kinases, in-house profiling requires rigorous kinase assay development.READ MORE
Assessment of Oral LISPRO Treatment in Ameliorating Amyloid and Tau Pathology in Transgenic Alzheimer’s Mice ModelPoster
Ionic co-crystals of lithium salicylate with organic proline (LISPRO) showed better safety and pharmacokinetic profile of lithium in plasma and brain of wild-type and transgenic Alzheimer mice model compared to lithium salts.READ MORE
CiPA Phase 2 Study: validation of an automated microelectrode array (MEA) assay of hiPSC-derived cardiomyocyte electrophysiology for cardiac safety evaluationPoster
These results support the use of hSC-CM and MEA technology for preclinical assessment of proarrhythmic risk within the proposed CiPA paradigm, and, more generally, demonstrate that automation of the CM-MEA assay can achieve high reliability and throughput for cardiac risk assessment in vitro.READ MORE